To test the hypothesis that person-to-person variability in blood levels of hepatitis C virus (HCV) RNA can be explained, the quantity of HCV RNA was assessed in 969 persons who acquired HCV infection in the context of injection drug use. Serum HCV RNA levels ranged from 200,000 to 1120 million equivalents/mL (the linear range of the assay). The median log 10 HCV RNA level was 0.46 higher in 468 human immunodeficiency virus (HIV)-positive persons than in 501 HIV-negative persons ( ). In addition, among HIV-negative persons, lower P ! .001 HCV RNA levels were independently associated with younger age ( ), ongoing hepatitis P ! .001 B infection ( ), and the absence of needle sharing ( ). However, 190% of the P = .005 P = .02 person-to-person HCV RNA level variability was not explained by these sociodemographic, environmental, and virologic factors. Additional research is necessary to ascertain what determines the level of HCV RNA in blood.
It is estimated that persons infected with human immunodeficiency virus (HIV) make 10 11 virus particles a day [1] . The serum HIV level, which represents the equilibrium of virus production and clearance, is the strongest predictor of clinical outcome. Persons with low serum HIV RNA levels are more likely to clear viremia with treatment and less likely to acquire opportunistic infections [2] [3] [4] [5] . Determinants of HIV levels have been investigated, and host genetic polymorphisms and sex differences have been described elsewhere [6, 7] . For example, Farzadegan et al. [6] found that HIV RNA levels were lower among women.
It is also estimated that persons infected with hepatitis C virus (HCV) make 10 12 HCV particles a day [8] . As with HIV, a low serum HCV RNA level has been associated with improved treatment response [2, 9] . However, the association between serum RNA level and disease progression is less evident with HCV than with HIV and has not been found in all investigations [10] [11] [12] [13] .
The variability in research findings may be explained by dif-ferences in factors that determine the level of serum HCV RNA, which may vary by up to 6 orders of magnitude among untreated persons. However, although the HCV RNA level is an important indicator of treatment response and a possible indicator of the natural history of infection, there have been few studies to ascertain the regulating factors. To test the hypothesis that the level of HCV RNA differs according to virologic, environmental, or sociodemographic factors, serum HCV RNA quantities were assessed in a large cohort of HCV-infected persons who were at risk for HIV and hepatitis B virus (HBV) infections.
Research Methods
Participants. Since 1988 Since -1989 , members of a cohort of former and current injection drug users in the AIDS Linked to the Intravenous Experience (ALIVE) study have been followed semiannually at Johns Hopkins University (Baltimore) [14] . At enrollment, the cohort was 81% male, 90% black, and 25% HIV positive; median age was 34 years and median duration of injection drug use was 13 years. A standardized questionnaire, administered at enrollment and readministered in modified form at each visit, elicited the following patient characteristics: sex, age, race, illicit drug use (including frequency of use, years of use, and specific information regarding method of heroin and cocaine use), methadone use, alcohol use (including information regarding frequency and quantity), and tobacco use. Members of the original 1988-1989 cohort with у1 visit between January 1995 and March 1996, when serum samples were obtained for HCV RNA studies, were included in this analysis.
Laboratory studies. Blood was obtained from study participants at study visits and sent to a regional commercial laboratory (Quest Diagnostics, Baltimore) for liver enzyme testing. Liver enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and g-glutamyl transferase (GGT), were eval-uated within 24 h of serum procurement by a multichannel chemistry analyzer (model 5200; Olympus, Lake Success, NY). At least 3 serum aliquots were also stored within 2 h of procurement at Ϫ20ЊC for !1 week and then transferred without thawing to a permanent repository and stored at Ϫ80ЊC. HCV antibody was tested by use of EIA (Ortho Diagnostic Systems, Raritan, NJ) on samples taken at enrollment and on subsequent visits for seronegative participants as described elsewhere [15] . HIV testing was also performed at each study visit for HIV-negative participants, and CD4 lymphocyte counts were measured in HIV-positive participants as described elsewhere [14] . Sera were also tested at enrollment for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core, and antibody to HBsAg by commercial kits (Abbott Laboratories, Abbott Park, IL), as described elsewhere [16] . Serum samples from the same visit that were tested for HCV RNA level were also tested for HBsAg for those who were capable of being chronic carriers, including those who were HBsAg positive or negative for all 3 markers at enrollment.
HCV RNA levels were determined on previously unthawed serum aliquots collected at consecutive study visits from January 1995 through March 1996 (further described in Results). Baseline values refer to the first specimen tested per subject. HCV RNA levels were assayed by 1 technician according to the manufacturer's instructions (bDNA Quantiplex HCV RNA 2.0; Bayer Diagnostics, Emeryville, CA) [17] ; the assay uses synthetic oligonucleotide probes to bind HCV RNA molecules to a solid phase. A second set of probes hybridizes HCV RNA to a branched DNA amplifier, which generates signal (chemiluminescence) that is proportional to the quantity of HCV RNA in the sample. The HCV RNA level is assigned units of equivalents per milliliter (eq/mL); the assay has a linear range of 200,000 to 120 million eq/mL. All samples were run in duplicate, and the average of the 2 values was reported as the HCV RNA level. If the coefficient of variance between the 2 samples exceeded 20%, testing was repeated.
HCV genotype was assessed by restriction length polymorphism according to the method of Davidson et al. [18] . On a subset of 42 participants, HCV genotype was also ascertained by phylogenetic analysis of core-E1 sequence, as described elsewhere [19] . Core-E1 sequence was also assessed by the same method to examine whether reinfection occurred in a subset of participants who acknowledged ongoing drug use and needle sharing. HCV sequence corresponding to the putative NS5A interferon sensitivitydetermining region (ISDR) was amplified, as described with core-E1, with the following modifications-Hotstar Taq (Qiagen, Valencia, CA) was used with the following primers: 5 -CRKCBCC-YGAATTYTTCAC-3 (nt 6691-6710) and 5 -TCGAARGAGT-CCAGRATYAC-3 (nt 7131-7111) and cycling conditions 15 min 95ЊC, then 70 cycles of 94ЊC 15 s, 62Њ-52ЊC for 30 s stepping down by 2ЊC every four cycles until the final annealing temperature was reached, 72ЊC for 1 min. Degenerate primers are indicated with standard codes of the International Union of Pure and Applied Chemistry. Nucleotide positions are relative to HCV-1 (accession no. M62321).
Statistical analysis. The overall distribution of HCV RNA levels was examined in HCV antibody-positive participants who had HCV RNA detectable by bDNA assay. HCV RNA levels exceeding the linear range of the assay were assigned 120 million eq/mL, the highest recorded value, whereas participants with baseline HCV RNA levels not detected by bDNA were excluded. HCV RNA levels were log 10 transformed to approximate a normal distribution, but they remained skewed among HIV-positive participants. Thus, statistical comparisons were made by nonparametric tests (Kruskal-Wallis and Spearman's rank). Liver enzymes were categorized into clinically meaningful groups as normal, 11.5 times normal, and others, whereas other continuous variables were categorized into quartiles. The categorical format was shown in tables for consistency with other variables and to optimally demonstrate the magnitude of differences in distribution. However, for liver enzymes, the correlation with HCV RNA level was also expressed in text as Spearman's correlation coefficient.
The independence of the association of variates that appeared to be correlated with HCV RNA level on univariate analysis was further assessed by fitting multivariate linear regression model of the log 10 HCV RNA levels. Because of the skewed distribution of data, this analysis was repeated by using a nonparametric multivariate analysis of the rank order of HCV RNA levels, and similar results were obtained. However, because the parameter estimates provide a more meaningful representation of the magnitude of effects, the nonparametric linear regression model is shown. The degree to which the final model explained the overall variance was indicated by the adjusted r 2 .
Results
The quantity of HCV RNA was evaluated in 969 anti-HCVpositive persons with HCV RNA detectable by bDNA. Cohort members were excluded from this analysis if they had HCV RNA levels that were undetectable by bDNA ( ), were n = 135 anti-HCV negative (
), or were not tested for anti-HCV n = 72 ( ). The sociodemographic, drug use, and serologic status n = 3 of participants with HCV load investigation are shown in table 1. The age, sex, drug use patterns, and income of study participants were similar to the original cohort at enrollment. However, the subset under study was more likely to be HIV positive at enrollment. By 1995 when HCV levels were assessed, 48% were HIV positive and 36% had !200/mL CD4 lymphocytes. No study members were being treated for HCV infection during the interval of quantitative HCV RNA testing. Overall, the median HCV RNA level in the cohort was 9.3 million eq/mL. Values spanned the linear range of the assay and included 17 participants with HCV RNA levels above the range, who were assigned the value of the upper limit, 120 million eq/mL.
HIV infection. The median HCV RNA level was higher (7.19 log 10 eq/mL) in 468 HIV-positive participants than in 501 HIV-negative persons (6.73 log 10 eq/mL;
; figure 1 ). P ! .001 However, among HIV-positive participants, increased HCV RNA levels were not detected in those with lower CD4 lymphocyte counts (  ; table 2 ). Similarly, among HIV-positive P 1 .1 participants, no significant differences in HCV RNA levels were detected by age, race, sex, alcohol or drug use, HCV genotype, or HBsAg status. Statistically significant ( ) associations P ! .01 were observed between HCV RNA level and the serum AST and GGT but not with serum ALT; however, the magnitude of each liver enzyme correlation was small (Spearman's correlation coefficient, ).
2 r ! 0.25 HIV-negative participants. Among 501 HIV-negative participants, HCV RNA levels were higher in older participants, males, HBsAg-negative persons, and those with high risk drugusing practices (sharing needles; table 3). However, after adjusting for age, males no longer had significantly higher HCV RNA levels (table 4). Older age and needle sharing were independently associated with higher HCV RNA levels, whereas serum HBsAg detection was inversely associated. No significant differences were detected in HCV RNA levels among participants with different alcohol use patterns. As observed among HIV-positive participants, a statistically significant association was detected between the level of HCV RNA and serum GGT, but not AST or ALT. However, the magnitude of each liver enzyme correlation was small ( ).
2 r ! 0.25 No differences were detected in the HCV RNA levels by HCV subtype. To further examine the hypothesis that polymorphisms in the NS5A ISDR correlate with viral load differences, we compared the sequences of 14 HIV-negative participants in the highest viral load quartile with HCV subtype-, age-, sex-, and HBsAg status-matched control subjects who had HCV RNA levels in the lowest quartile. No differences were noted (figure 2).
To estimate the degree to which the factors assessed in this investigation accounted for the person-to-person variability in HCV RNA levels, a linear regression model was constructed of all variates associated with the log 10 HCV RNA levels on univariate analysis. However, in this model that contained HIV infection, HBsAg status, age, and needle sharing, !10% of the variance in HCV RNA was accounted for (adjusted r 2 , 0.085). Change in HCV RNA over time. In total, 687 participants had 11 HCV RNA level in the linear range of the bDNA assay: 473 had 2 tests and 214 had 3 tests constituting 901 pairs. The median (interquartile range [IQR] ) time between the 901 visits was 5.7 months (range, 5.5-6.0 months). From visit to visit, the median (IQR) change in the magnitude of the HCV RNA level was 0.26 log 10 (range, 0.12-10 log 10 ). By using the first pair of visits, participants who reported injection drug use in the interval between HCV RNA assessments had higher visitto-visit differences than those who did not report injection drug use ( ), but this difference was small (0.27 vs. 0.23 log 10 , P = .038 respectively). No differences were detected in visit-to-visit HCV RNA variance according to HIV or HBV infections, alcohol use, or sociodemographic factors (data not shown). During the relatively short observation period, nearly equal proportions of participants experienced increases or decreases in HCV RNA level; the median intervisit slope per semester of follow-up (IQR) was Ϫ0.029 log 10 (range, Ϫ0.233 to 0.178 log 10 ). 
NOTE.
Statistical comparisons of log-transformed HCV RNA levels were made by Kruskal-Wallis test. Continuous variables were assessed with log-transformed HCV RNA levels by Spearman's correlation (see text). Continuous variates were categorized for consistency as follows: age and years from first injection drug use by quartile, alcohol use to differentiate у3 daily drinks from other use, and liver enzymes (ALT, AST, and GGT) as less than upper limit of normal (ULN), , and . Difference between 468 and sum of ! 1.5 ϫ UNL 1 1.5 ϫ UNL column 2 represents no. with data missing for each variate. IQR, interquartile range.
a Refers to practices in 6 months before collection of serum samples tested for HCV RNA level.
To further examine the possibility that HCV reinfection occurred and explained changes in HCV RNA levels, we examined the genetic distances in core-E1 sequence between paired serum samples from 20 participants who acknowledged ongoing drug use and needle sharing between visits. Ten participants were chosen from HCV genotype 1a and 10 from HCV genotype 1b; the mean time between visits was 6 months (SD, 3 weeks), and there was a mean of 491 injections (SD, 317 injections). Seven participants had intervisit HCV RNA level differences у0.5 log 10 . The intervisit genetic distance was similar to previously observed genetic distances among individual viral variants within a specimen and were lower than intersubject genetic distances (figure 3) [20] . However, the intervisit genetic distances of these 20 participants were lower than all possible intersubject comparisons of the 10 HCV 1a participants.
Discussion
In this large-scale investigation of HCV-infected participants, the largest differences in serum HCV RNA levels were between HIV-positive and -negative persons. This finding was expected, since in 29 members of this cohort we previously observed that HCV RNA levels increased after HIV infection was acquired [21] . Similarly, others have found higher serum HCV RNA levels in HIV-positive persons [22, 23] .
Among HIV-positive persons in this study, no significant correlates of serum HCV RNA level were detected. A relationship was expected with CD4 lymphocyte counts, since we previously found an inverse association (albeit small) in 29 HIV seroconverters, and Eyster et al. [21, 22] demonstrated a strong inverse correlation between CD4 lymphocyte count and serum HCV RNA level in hemophiliacs. The lack of association with CD4 lymphocyte count in the present analysis may reflect changes in the HIV-positive cohort (survival bias). In our former investigation, we only studied persons whose onset of HIV infection was known and a subset with rapid progression of HIV infection. In contrast, the present study only includes participants who survived to the initiation of this study. Of interest, others have also failed to detect an association between HCV serum RNA level and CD4 lymphocyte count in HIV-positive persons [23] [24] [25] .
In HIV-negative persons, higher serum HCV RNA levels were found among older participants. In this cohort, age was a strong correlate of the length of drug use and with duration of HCV infection [26] , suggesting that the level of serum HCV RNA may increase over time from HCV infection. Others have reported findings to support this hypothesis [27] . Although the median intervisit slope observed in this study was relatively stable, the observation time was short (!2 years). Our findings could also be consistent with age-related immunosuppression, since other biologic differences (e.g., vaccine responses) have been described within this age range. In either case, these data emphasize the importance of controlling for age in evaluations NOTE. Statistical comparisons of log-transformed HCV RNA levels were made by Kruskal-Wallis test. Continuous variables were also assessed with logtransformed HCV RNA levels by Spearman's correlation (see text). Continuous variates were categorized for consistency as follows: age and years from first injection drug use by quartile, alcohol use to differentiate у3 daily drinks from other use, and liver enzymes (ALT, AST, and GGT) as within upper limit of normal (UNL), , and . Difference between 501 and sum ! 1.5 ϫ UNL 1 1.5 ϫ UNL of column 2 represents no. with data missing for each variate. IQR, interquartile range.
a Refers to practices in 6 months before collection of serum samples tested for HCV RNA level. of HCV RNA level and underscore the need for prospective investigations of the relationship between HCV RNA level and disease outcome.
The association of serum HBsAg positivity with lower HCV RNA level has been reported elsewhere [28] [29] [30] [31] [32] . Because HBsAg was inversely associated with age in this cohort, it was important that the correlation of HBsAg and lower HCV RNA level was independent of age. Although a virologic interaction has been proposed, the data in this study do not provide insight into the biologic basis for this relationship.
In this investigation, serum HCV RNA level was also positively associated with needle sharing. Among injection drug users, needle sharing could be a marker for HCV reinfection, which has been demonstrated in humans with thalassemia and in chimpanzees [33, 34] . Supporting this hypothesis are the lack of association of HCV load with drug use without needle sharing, the lack of association with drug type (heroin or cocaine), and the additional association with use of a shooting gallery, another plausible marker for HCV reinfection (data not shown). No evidence for HCV reinfection was found in the majority of core-E1 sequences of 20 participants with ongoing drug use and needle sharing. Although these data may suggest other explanations for the association between drug use and HCV RNA level, it is impossible to exclude reinfection, since a limited number of participants were assessed and all variants in the HCV quasispecies could not be examined. Fortunately, the proportion of participants actively injecting drugs decreased over the course of follow-up.
Women in this cohort had lower serum HIV RNA levels [6] . However, unlike HIV RNA levels, after adjusting for age, no sex difference was detected in the level of HCV RNA [6] . It was also anticipated that alcohol use and HCV genotype might be associated with higher HCV RNA level, since these associations have been found in some, but not all, prior studies [35] [36] [37] . If the alcohol effect on HCV replication was short lived and alcohol use was irregular in the cohort, the association could have been missed, since alcohol use was assessed as it occurred in the 6 months before RNA testing. Since ∼90% of the cohort have genotype 1 HCV infection, differences in HCV RNA level between HCV genotypes would be difficult to detect.
This analysis was designed to assess determinants of HCV RNA levels, not the relationship between the progression of HCV infection and HCV RNA level. The correlation of HCV , injections) between 2 visits mean of 6 months apart SD 491 ‫ע‬ 317 ‫3ע(‬ weeks). ࡗ, Intrasubject distances represent core-E1 sequences from clones with different hypervariable region-1 sequences from previous study [20] . ᭝, Intersubject distances are pairwise distances between 10 genotype 1a participants in this study.
RNA level with liver enzymes was considered. Although a statistically significant positive correlation was found with GGT and, with HIV-positive participants, AST, the strength of each correlation was weak (
). In addition, liver enzymes are It is unlikely that the results of this investigation were substantially altered by technical limitations. Although some specimens were stored at Ϫ80ЊC for 2 years before testing, recent data suggest that storage does not affect the HCV RNA level determined by bDNA [38] . Repeated thawing and prolonged time before centrifugation have been associated in some, but not all, studies with lower HCV RNA levels [38] [39] [40] . However, in this investigation, testing was on an aliquot not previously thawed, and serum samples were centrifuged and frozen within hours of collection.
Although the analytic sensitivity of the bDNA assay is limited, most individuals (88% of study participants) have HCV RNA levels within the linear range of the assay, making it optimal for a study of HCV RNA levels. Additional testing will be necessary for participants with RNA levels less than the bDNA linear range, to ascertain whether they have cleared infection or have low RNA levels. Exclusion of participants with HCV RNA levels below the level of detection of the assay ensures that this study did not assess both determinants of HCV RNA level and HCV RNA clearance, 2 distinct processes. On the other hand, inclusion of participants with HCV RNA levels above the level of detection should not substantially affect the results, since median values were compared and the nonparametric statistical tests consider the rank order of levels rather than their absolute value. In this investigation, serum HCV RNA levels ranged from !200,000 to 1120 million eq/mL. Although numerous virologic, environmental, and sociodemographic variables were considered and significant correlates were identified, !10% of the overall interperson HCV RNA variability was explained. Little visitto-visit variance was noted in the subset of participants with у2 HCV RNA assessments and, since the samples were all run in duplicate, only a small proportion of the variance can be attributed to the assay. Polymorphisms in the putative NS5A ISDR have been variably associated with differences in HCV RNA level in prior studies [41] [42] [43] . However, these sequences are usually similar within HCV subtypes, and we found no subtype differences in HCV RNA levels. In addition, among carefully matched, HIV-negative participants within a given subtype, no association was found between the serum level of HCV RNA and the NS5A amino acid sequence. Collectively, these findings indicate that serum HCV RNA levels are chiefly determined by factors not assessed in this investigation. In summary, HIV infections, HBV infection, age, and highrisk drug use practices need to be considered in future evaluations of HCV RNA levels. Further research is needed to understand the mechanisms through which these factors affect HCV RNA levels and to ascertain conditions not measured in this study that chiefly determine HCV RNA level in blood.
